Abstract
Introduction
Genomics has paved the way for its cousin, proteomics, to secure its share of
the "omics" hype. Researchers look to proteomics to deliver on the promise to
assess the viability of drug targets for monitoring disease progression,
optimizing disease management, and diagnosing diseases with more precision.
While many challenges are inherent, given the complexities of protein-centric
science, technological improvements in the fi eld have resulted in important
gains for biopharma.
Get the Answers You Need to Shape Your Strategy
- Partnering in proteomics is slowing despite the potential of the
associated technologies to revolutionize drug discovery, diagnostics
development, and disease management. What problems are inherent in protein
biomarker research? What solutions have been developed to help overcome the
obstacles?
- Navigating the proteomics research process of preparation, separation,
identifi cation, and validation is complex. Which step is most critical
upstream to improve results downstream?
- Proteomics technologies give rise to a select set of protein biomarkers.
What are the differences between biomarkers for drug discovery and those for
diagnostics development?
Scope
- Proteomics technologies: 2DGE, MS, MALDI, SELDI, TOF, bioinformatics.
- Proteomics research process: Innovative methods of sample preparation,
separation and capture, identifi cation and analysis, and clinical validation.
- Companies with valuable insight into protein biomarker discovery:
20/20GeneSystems, Caprion Proteomics, NextGen BioSciences, Oxford
GlycoSciences.
- Outlook: Proteomics is approaching the long-awaited recognition that it
has the potential to deserve. Novel tools now in use will improve greatly
owing to collaborative initiatives that will stimulate innovation in protein research processes.
| 
View Cart
